All News
Filter News
Found 90 articles
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Freeline Appoints Paul Schneider as Chief Financial OfficerBiotech executive with robust experience in financial and corporate strategy and operational excellence will strengthen the company’s leadership team
4/19/2022
Freeline Therapeutics Holdings plc announced that Paul M. Schneider has been appointed Chief Financial Officer, effective May 16, 2022, based in Boston.
-
ILIAS Biologics Inc. Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Exosome Therapeutics ILB-202, the Treatment for CSA-AKI
4/7/2022
ILIAS Biologics Inc., announced today that it has received approval by the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1, the first-in-human trial of ILB-202, exosome therapeutics for the treatment of cardiac surgery-associated acute kidney injury (AKI).
-
Exo Therapeutics’ approach is not only different, it has revolutionary potential.
-
Exo Therapeutics Appoints Antonio Gualberto as President of Research & Development and Chief Medical Officer
1/18/2022
Exo Therapeutics, Inc. today announced the appointment of Antonio Gualberto, MD, PhD, as President of Research & Development and Chief Medical Officer.
-
Newpath is guided by the ethos: “Do the right thing and good things will happen."
-
BioSpace Movers & Shakers, Oct. 29
10/29/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Exo Therapeutics Appoints Dorothy Lou Bailey as Senior Vice President, Corporate Development and Strategy
10/26/2021
Exo Therapeutics, Inc. today announced the appointment of Dorothy Lou Bailey as Senior Vice President, Corporate Development and Strategy.
-
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting
10/18/2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Therapeutic Benefits of MSC-NTF (NurOwn®) Exosomes in Acute Lung Injury Models" at the NYSCF 2021 VIRTUAL Meeting, being held on October 19-20, 2021.
-
These life sciences companies scored enough capital this week for pumpkin spice and everything nice, and to propel their candidates in the clinic. Here's a look.
-
Novartis-backed Exo Therapeutics closed out 2020 by completing a $25 million Series A financing round. Nearly 10 months later, the small molecule drug discovery and development company has earned more support from investors.
-
Exo Therapeutics Raises $78 Million Series B Financing
10/5/2021
Exo Therapeutics, Inc., a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets, announced the completion of a $78 million Series B financing.
-
Alpha Healthcare and Humacyte Announce Nominees for Election to Post-Merger Public Company Board of Directors
8/13/2021
Alpha Healthcare Acquisition Corp. today announced the nominees who will stand for election/reelection to its Board of Directors during the August 24, 2021, AHAC special shareholder’s meeting to vote on the proposed business combination with Humacyte, Inc.
-
Show me the money! This week's who's who of IPOs and financing rounds in the biopharma world.
-
Keystone Bio Advances a More Complete Explanation of Porphyromonas Gingivalis Toxic Virulence Factors as Major Driver of Sporadic Alzheimer’s and Chronic Inflammation
7/29/2021
Keystone Bio, a biotechnology company, is a frontrunner in developing precision biologics to eliminate Porphyromonas gingivalis (Pg), and is releasing groundbreaking data that shows bacterial toxic proteins from Pg in the mouth are released into the blood and cross the Blood Brain Barrier (BBB) as the major driver of sporadic Alzheimer’s and chronic inflammation.
-
Abata Therapeutics Strengthens Board of Directors
7/28/2021
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that it has strengthened its board of directors with the addition of Nagesh Mahanthappa Ph.D., M.B.A., and Valerie Odegard, Ph.D.
-
ILIAS Biologics Inc. demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury
6/28/2021
Anti-inflammatory exosomes could have a place in treating acute kidney injury (AKI) caused by ischemia repercussion injury (IRI), according to a study done by ILIAS Biologics, Inc. in collaboration with Yonsei University of Seoul, South Korea.
-
Exo Therapeutics Appoints Nagesh Mahanthappa to Board of Directors and Charles W. Roberts to Scientific Advisory Board
3/30/2021
Exo Therapeutics , Inc., a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets, today announced the appointment of Nagesh Mahanthappa, PhD, to the company’s Board of Directors (BOD) and Charles W. Roberts, MD, PhD, to the company’s Scientific Advisory Board (SAB).
-
ILIAS Biologics announces the 2nd POC study, showing anti-inflammatory effects of ILB202 on preterm birth
2/1/2021
ILIAS Biologics, Inc. announced that its latest research in collaboration with researchers at The University of Texas Medical Brand at Galveston (UTMB) is published in the journal Science Advances(Link: https://advances.sciencemag.org/content/7/4/eabd3865).
-
Launching with hearty Series A rounds, these new companies are ready to run.